It has been reasoned that it makes more commercial sense to treat chronic conditions requiring years of therapy rather than curing diseases with short courses of treatment.
After all, even the most stubborn of bacterial infections rarely, if ever, require more than six months of treatment, and the average course of therapy is under seven days. This well-noted futility has led some to suggest that this approach will never prove productive, that the majority of “novel” targets are not “druggable,” and that industry research dollars are better spent elsewhere. To date no antibacterial compounds identified by target based screening have advanced into clinical testing much less been used clinically to treat bacterial infections.
0 kommentar(er)
